Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Forte Biosciences
Biotech
Argenx’s phase 2 celiac win tees up pivotal run for $2.2B drug
Argenx hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences.
Nick Paul Taylor
Oct 8, 2026 3:03am
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug
Jul 27, 2026 6:08am
Fierce Biotech's Rotten Tomatoes of 2022
Dec 19, 2022 3:00am
Forte taps new exec amid shareholder dissent—Chutes & Ladders
Jun 10, 2022 9:30am
Forte's top shareholder calls on the company to liquidate
May 25, 2022 11:29am
Forte's lead atopic dermatitis therapy fails phase 2
Sep 2, 2021 4:38pm
